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Abstract
Aims/hypothesis Pancreatic islet beta cell failure causes type 2
diabetes in humans. To identify transcriptomic changes in type
2 diabetic islets, the Innovative Medicines Initiative for
Diabetes: Improving beta-cell function and identification of
diagnostic biomarkers for treatment monitoring in Diabetes
(IMIDIA) consortium (www.imidia.org) established a
comprehensive, unique multicentre biobank of human islets
and pancreas tissues from organ donors and metabolically
phenotyped pancreatectomised patients (PPP).
Methods Affymetrix microarrays were used to assess the islet
transcriptome of islets isolated either by enzymatic digestion
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from 103 organ donors (OD), including 84 non-diabetic and
19 type 2 diabetic individuals, or by laser capture microdis-
section (LCM) from surgical specimens of 103 PPP, including
32 non-diabetic, 36 with type 2 diabetes, 15 with impaired
glucose tolerance (IGT) and 20 with recent-onset diabetes
(<1 year), conceivably secondary to the pancreatic disorder
leading to surgery (type 3c diabetes). Bioinformatics tools
were used to (1) compare the islet transcriptome of type 2
diabetic vs non-diabetic OD and PPP as well as vs IGT and
type 3c diabetes within the PPP group; and (2) identify tran-
scription factors driving gene co-expression modules correlat-
ed with insulin secretion ex vivo and glucose tolerance
in vivo. Selected genes of interest were validated for their
expression and function in beta cells.
Results Comparative transcriptomic analysis identified 19
genes differentially expressed (false discovery rate ≤0.05, fold
change ≥1.5) in type 2 diabetic vs non-diabetic islets from OD
and PPP. Nine out of these 19 dysregulated genes were not
previously reported to be dysregulated in type 2 diabetic islets.
Signature genes included TMEM37, which inhibited Ca2+-in-
flux and insulin secretion in beta cells, and ARG2 and
PPP1R1A, which promoted insulin secretion. Systems biolo-
gy approaches identified HNF1A, PDX1 and REST as drivers
of gene co-expression modules correlated with impaired insu-
lin secretion or glucose tolerance, and 14 out of 19 differen-
tially expressed type 2 diabetic islet signature genes were
enriched in these modules. None of these signature genes
was significantly dysregulated in islets of PPP with impaired
glucose tolerance or type 3c diabetes.
Conclusions/interpretation These studies enabled the strin-
gent definition of a novel transcriptomic signature of type 2
diabetic islets, regardless of islet source and isolation
procedure. Lack of this signature in islets from PPP with
IGT or type 3c diabetes indicates differences possibly due to
peculiarities of these hyperglycaemic conditions and/or a role
for duration and severity of hyperglycaemia. Alternatively,
these transcriptomic changes capture, but may not precede,
beta cell failure.
Keywords Beta cell . Biobank . Diabetes . Gene expression .
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Introduction
The interplay of genetic and environmental factors leads to
impaired beta cell function and viability, which are the
ultimate and possibly primary causes of type 2 diabetes
[1–3]. Studies of post-mortem pancreases from non-
diabetic and type 2 diabetic individuals [4, 5] as well as
acute diabetes reversal following bariatric surgery [6], pan-
createctomy [7] or severe nutrient restriction [8] have chal-
lenged the notion that beta cell death is the major cause of
type 2 diabetes. Instead, insufficient insulin secretion in
type 2 diabetes has been attributed to beta cell dysfunction
due to various mechanisms, including de-differentiation [9,
10].
Early studies of islets from non-diabetic (≤7) and type 2
diabetic (≤6) organ donors reported the downregulation
(p < 0.01) in type 2 diabetic islets of HNF4A and ARNT
[11], known to regulate exocytosis, mitochondrial activity
[12, 13] and islet structure and function [14]. Groop and
collaborators correlated the transcriptome of islets from 54
non-diabetic and nine type 2 diabetic organ donors with
ex vivo insulin secretion and clinical features, including
HbA1c [15]. The same group also compared the islet tran-
scriptome of 51 non-diabetic individuals, 12 type 2 diabetic
individuals and 15 people with an HbA1c of 6.0–6.5% (42–
48 mmol/mol) [16]. These studies found several genes to be
differentially expressed in type 2 diabetic islets, including
some related to insulin secretion and/or HbA1c [15, 16], beta
cell apoptosis [17] and beta cell proliferation [18, 19].
Furthermore, in type 2 diabetic islets, they described upregu-
lation of SFRP4, which might link islet inflammation to beta
cell dysfunction [20].
Two recent studies analysed the transcriptomes of single
islet cells from 12 or six non-diabetic individuals, and six or
four type 2 diabetic organ donors, respectively [21, 22], and
identified 48 [21] or 75 [22] differentially expressed tran-
scripts in type 2 diabetic islet beta cells. Only one gene
(FXYD2) was regulated in both studies, but in the opposite
direction. Thus, a consensus on transcriptomic alterations in
type 2 diabetic beta cells is still lacking. In fact, seven tran-
scripts reported as being regulated (non-overlapping between
the two studies) had previously been found to be dysregulated
in type 2 diabetic vs non-diabetic beta cells yielded by laser
capture microdissection (LCM) from ten non-diabetic and ten
type 2 diabetic organ donors [23].
While all these studies [11–23] provided insights into
the molecular changes of islets and beta cells in type 2
diabetes, diversity in the number of cases, islet and cell
handling, platforms and analytic procedures could account
for their different outcomes. Furthermore, transcriptomic
data were generally obtained from enzymatically isolated
islets; in just one instance, beta cells were retrieved by
LCM [23]. To identify robust gene expression changes in
type 2 diabetic islets independent of recruitment centre,
source (organ donor vs phenotyped pancreatectomised pa-
tients [PPP]) and isolation procedure (enzymatic digestion
vs LCM), the Innovative Medicines Initiative for Diabetes:
Improving beta-cell function and identification of diagnostic
biomarkers for treatment monitoring in Diabetes (IMIDIA)
consortium (www.imidia.org) established a large
multicentre biobank of human islets from organ donors
and PPP. The aim of this innovative approach was to
identify consistent transcriptomic changes in type 2
diabetic islets and to evaluate their presence in islets from
PPP with glucose intolerance or type 3c diabetes.
Methods
For detailed Methods, please refer to the electronic supple-
mentary material (ESM).
Islet procurement, insulin secretion and RNA extraction
Pancreases unsuitable for transplantation were obtained in
Pisa from 161 non-diabetic and 39 type 2 diabetic heart-
beating organ donors (OD) with the approval of the local
ethics committees. Type 2 diabetes was diagnosed based
on clinical history, treatment with glucose-lowering drugs,
and lack of anti-GAD65 autoantibodies. Islets were suc-
cessfully isolated from the pancreases of 153 non-diabetic
and 34 type 2 diabetic OD by enzymatic digestion and
density gradient purification, and their insulin secretion
was assessed using an immunoradiometric assay, as pre-
viously described [5, 24]. RNA was purified 2–3 days
after islet isolation (see ESM Methods for further
details). Forty-three additional human islet preparations,
all from non-diabetic OD, were acquired by Eli Lilly from
Prodo Laboratories (Irvine, CA, USA). Please see ESM
Methods for further details.
Pancreatic surgical specimens were obtained in Dresden
from 201 PPP following patients’ informed consent and
approval by the local ethics committee. Islets specimens
were retrieved by LCM from snap-frozen surgical speci-
men of 117 PPP (37 non-diabetic, 41 type 2 diabetic, 16
with impaired glucose tolerance (IGT) and 23 type 3c
diabetic individuals) and their RNA was purified as previ-
ously described [25]. Please see ESM Methods for further
details.
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Human islet beta and alpha cell-enriched fractions were
prepared from islets isolated in Pisa from OD, as previously
described [26] (see ESM Methods, for more details).
RNA sequencing of OD islets exposed ex vivo to
hyperglycaemia Three independent islet preparations from
non-diabetic OD (age: 80 ± 4 years, sex: 1 female/2 male,
BMI: 22.7 ± 0.6 kg/m2) were used to assess islet gene expres-
sion after exposure to 22.2 mmol/l glucose vs 5.5 mmol/l
glucose (see ESM Methods for further details).
Microarrays RNA was extracted from the islet samples,
processed and subjected to transcriptomic profiling as described
in the ESM Methods (‘Extraction of RNA from islets isolated
enzymatically or by LCM from PPP surgical specimens’. and
‘RNA quality assessment, processing and transcriptomic pro-
filing’). Microarray findings were validated by transfection of
cDNA vectors in Chinese hamster ovary [CHO] cells (ARG2,
PPP1R1A and TMEM37) and INS-1 832/13 cells
(Tmem37-V5) or silencing RNAs in INS-1 832/13 (Arg2,
Ppp1r1a and Tmem37) and EndoC-βH1 cells (ARG2,
PPP1R1A and TMEM37), Ca2+ imaging, reverse transcription
quantitative PCR (RT-qPCR) (ACTB, ANKRD23, ANKRD39,
ARG2, ASCL2, CAPN13, CD44, CHL1, FAM102B, FBXO32,
FFAR4, G6PC2, HHATL, HNF1A, KCNH8, NSG1, PCDH20,
PDX1, PPP1R1A, SCTR, SLC2A2, TMEM37,UNC5D), in situ
RT-PCR (ARG2, ASCL2, CHL1-iso1, CHL1-iso2, CHL1-iso3,
FAM102B, FFAR4, HHATL, KCNH8, PPP1R1A, SCTR,
SLC2A2, TMEM37 andUNC5D), western blotting (V5 epitope
tag, γ-tubulin, pancreatic and duodenal homeobox 1 [PDX1]
and HNF1 homeobox A [HNF1A]), immunomicroscopy (insu-
lin, protein phosphatase 1 regulatory inhibitor subunit 1A
[PPP1R1A], transmembrane protein 37 [TMEM37], glucagon
and arginase 2 [ARG2]) and chromatin immunoprecipitation
(PDX1 and HNF1A). See the ESMMethods for further details.
Primers are listed in ESM Tables 1–4.
Data analysis
Processing and analysis of RNA sequencing data from is-
lets exposed ex vivo to hyperglycaemia Single-end reads
(75 bp) were aligned to human genomic sequence (hg19 as-
sembly) using TopHat and Bowtie2 (version 2.0.11 and ver-
sion 2.2.1, respectively; http://ccb.jhu.edu/software.shtml)
and using Samtools (version 0.1.19; http://samtools.
sourceforge.net/) for sorting of alignment files. Read counts
per gene were then generated using HTSeq (htseq-count
version 0.5.4p3; https://htseq.readthedocs.io/) and Ensembl
genome annotation 75 (http://feb2014.archive.ensembl.org/
index.html). Differentially expressed genes were detected
using either DESeq2 (version 1.15.51) or Limma (version 3.
30.12) from the Bioconductor software package (https://
bioconductor.org/) in the R statistical programming
environment (https://www.r-project.org/). For DESeq2,
single-end reads (75 bp) were aligned to human genomic se-
quence (hg38 assembly) using GSNAP (version 2017-03-17;
http://research-pub.gene.com/gmap/), and Ensembl
annotation 87 was used to detect reads spanning splice sites.
The uniquely aligned reads were counted with featureCounts
(version 1.5.2, Bioconductor) and the same Ensembl
annotation. The raw counts were normalised based on the
library size and testing for differential gene expression
between the two conditions, samples treated with glucose vs
control, was performed with the DESeq2 R package. For
Limma, the raw count data were first filtered for an average
of at least five reads in all the samples, normalised to library
size using the weighted trimmed mean of M-values (TMM)
method in edgeR (version 3.16.5, Bioconductor), and then
transformed to log2-cpm (counts per million reads) using the
voom function in R. Empirical Bayes moderated t statistics
and corresponding p values were then computed comparing
the samples treated with glucose to controls using the Limma
package in R. The p values were adjusted for multiple com-
parisons using the Benjamini–Hochberg procedure in R.
Normalisation and statistical analysis of microarray data
Transcriptomics data were normalised by Robust Multi-array
Average (RMA) in Array Studio software (Omicsoft, Cary,
NC, USA). Batch correction of microarray data was per-
formed using the Bioconductor package ComBat in R.
Elimination of technical outlier samples was performed at
two steps of the transcriptomics analysis. The criterion for
expression was an intensity value of >75% for ≥25% of the
samples in that group. Subsequently, islet samples from organ
donors with no previous history of diabetes but with blood
fructosamine >285 μmol/l or glucose >11.1 mmol/l were ex-
cluded from the analysis. Islet samples from non-diabetic/type
2 diabetic OD with insulin levels <1 SD from the within-
group mean were also excluded. For comparisons between
type 2 diabetic and non-diabetic OD islets, significant differ-
ences were defined as a change in expression of ≥1.5 after
correction for multiple hypothesis testing using the
Benjamini–Hochberg method (p ≤ 0.05). Principal compo-
nent analysis was performed using the prcomp in R. The
analysis of all islet sample types and of a single sample
type (islets from OD or PPP) was based on the intensities
of the probe sets after batch correction. Contamination of
islet samples with exocrine pancreatic tissue was deter-
mined using selected markers of exocrine and ductal cells,
as indicated in ESM Table 5.
Bioinformatics The bioinformatics analyses performed with
Ingenuity Pathway Analysis software (Qiagen, Hilden,
Germany) comprised gene ontology over-representation
analysis of differentially expressed genes; determination of
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enriched genes involved in insulin secretion; and pathway
analysis of differentially expressed genes. Other bioinformat-
ics analysis comprised prediction of binding sites for HNF1A
and PDX1 in type 2 diabetic islet signature genes; identifica-
tion of gene co-expression modules from OD islet and PPP-
LCM samples; generation of a trait module network; identifi-
cation of module hub genes and measurement of the overlap
with signature genes; and generation and merging of
sequence-based and library-based transcription factor net-
works. The signature genes were ANKRD23, ANKRD39,
ARG2, ASCL2, CAPN13, CD44, CHL1, FAM102B,
FBXO32, FFAR4, G6PC2, HHATL, KCNH8, NSG1,
PCDH20, PPP1R1A, SCTR, SLC2A2, TMEM37 and
UNC5D. See ESM Methods (‘Data analysis’ section) for fur-
ther details.
Results
The IMIDIA cohortsWe collected pancreatic specimens from
two cohorts (Fig. 1a and ESM Table 6). One cohort consisted
of 243 OD, including 204 non-diabetic and 39 with type 2
diabetes. As expected, blood fructosamine, a biomarker for
glucose levels in the days preceding organ donation, was great-
er in type 2 diabetic (222 ± 72 μmol/l, n = 11) than in non-
diabetic OD (180 ± 45 μmol/l, n = 46, p = 0.018). The second
cohort included 201 PPP who underwent pancreatectomy for
pancreatic diseases. Among PPP, 70 were non-diabetic, 54 had
type 2 diabetes, 30 had IGT, and 46 had diabetes that was likely
due to the pancreatic disorder leading to surgery (type 3c dia-
betes) [27] (see ESMMethods). A diagnosis of type 3c diabetes
was made if diabetes was first detected <1 year before the
symptoms, which led to surgery. Histopathology of the resected
tissue did not reveal insulitis in any PPP. Assessment of insulin
secretion by OD islets showed reduced release from type 2
diabetic beta cells in response to glucose or glibenclamide
(known as glyburide in the USA and Canada), but not to argi-
nine (ESM Fig. 1), complementing previous findings [24].
Islets were isolated from 141 OD (115 non-diabetic and 26
type 2 diabetic), and 117 PPP (37 non-diabetic, 16 IGT, 41
type 2 diabetic, 23 type 3 diabetic) by enzymatic digestion or
LCM. Following filter selection (see ESM Methods) the
transcriptomes of islets from 103 OD (84 non-diabetic and
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Fig. 1 Transcriptional profiling of islet samples using complementary
isolation techniques. (a) Overview of our approach. Islets from OD and
PPP were analysed by Affymetrix profiling to identify differentially
expressed (DE) genes. These data were combined with clinical and
functional data to identify gene co-expression modules correlated with
T2D-related traits. ‘Collag.’ refers to enzymatic digestion. ‘Common DE
genes’ refers to genes differentially regulated in T2D vs ND in both OD
and PPP islets. ‘Pathways/Upstream regulators’ refers to pathways
downstream of and regulatory genes upstream of gene co-expression
modules. (b, c). Principal component analysis of OD and PPP islets
isolated enzymatically or by LCM using all transcribed genes. Principal
component 1 (PC1) accounts for 49% of the total variance; PC2 accounts
for 4%. (b) LCM islet samples (green, PPP; orange, OD) cluster
separately from enzymatically isolated islet samples (orange, OD; grey,
PPP) regardless of patient origin. (c) Duplicate OD (orange) and PPP
(purple) samples isolated either enzymatically or by LCM are
highlighted, confirming that clustering is according to the isolation
method. DP, code for Dresden pancreatectomised patient samples; ND,
non-diabetic; PO, code for Pisa OD samples; T2D, type 2 diabetic
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19 type 2 diabetic), and 103 PPP (32 non-diabetic, 36 type 2
diabetic, 15 IGT, 20 type 3c diabetic) were profiled (Table 1).
Hence, in total we profiled the islet transcriptomes of 116 non-
diabetic OD (84) and PPP (32) and of 55 type 2 diabetic OD
(19) and PPP (36). Between the OD and PPP groups, the non-
diabetic and type 2 diabetic patients were similar in terms of
their age, BMI, and mean duration of diabetes (Table 1).
Among non-diabetic and type 2 diabetic PPP, the prevalence
of chronic pancreatitis and of benign/malignant tumours was
also similar (Table 1).
Differentially expressed genes in type 2 diabetic islets In
total, 4438 out of 29,529 probe sets, corresponding to 2976
unique genes, were differentially expressed in type 2 diabetic
vs non-diabetic OD islets (false discovery rate [FDR] ≤0.05).
Overall, the expression of 608 probe sets, corresponding to 444
gene annotations (of which 421 were regulated only in OD and
not in PPP; ESMTable 7) changed ≥1.5 fold (Fig. 2a and GEO,
accession number: GSE76896). Among the top 20 regulated
genes, 18 were downregulated, and two were upregulated
(ESM Table 8). A total of 1439 of 29,612 probe sets were
differentially expressed in type 2 diabetic compared with
non-diabetic PPP islets (FDR ≤0.05), corresponding to 1039
unique genes. Overall, the expression of 208 probe sets,
corresponding to 136 gene annotations (of which 113 were
regulated only in PPP and not in OD; ESM Table 7), changed
≥1.5 fold (Fig. 2a and GEO, accession number: GSE76896).
Among the top 20 expressed genes, 12 were downregulated
and eight upregulated (ESM Table 8). In type 2 diabetic OD
islets, 69% (307/444) of the differentially regulated genes were
downregulated, whereas 62% (84/136) of the differentially
regulated genes were upregulated in type 2 diabetic PPP islets
(Fig. 2a). Exocrine and ductal pancreatic markers were compa-
rably low in OD and PPP islets (see ESM Table 5).
Furthermore, islets isolated enzymatically from OD and PPP
clustered together by principal component analysis (PCA) and
separately from the cluster of islets isolated by LCM from the
same OD and PPP (Fig. 1b, c), suggesting the influence of the
isolation procedure (enzymatic for OD and LCM for PPP)
rather than differences between OD and PPP. Comparing
differentially expressed genes with pancreatic cancer
transcriptomic signatures (see ESM Results) we found no evi-
dence for contamination of PPP samples with cancer cells [28].
Dysregulated genes common to type 2 diabetic OD and
PPP islets To identify the most reproducible transcriptomic
changes in type 2 diabetic islets independent from covariates
such as islet retrieval procedure, tissue source and/or collecting
centre, we focused on genes significantly dysregulated in type
2 diabetic islets in both cohorts. This allowed us to identify 23
genes with an FDR of ≤0.05 and a fold change of ≥1.5, of
which 19 were dysregulated in the same direction in both type
2 diabetic OD and PPP islets (Table 2 and Fig. 2a). The reason
for the regulation in opposite directions of DAB1, GAP43,
PDK4 and RGS16 in type 2 diabetic OD and PPP islets is
unclear. Fifteen genes were downregulated, including
SLC2A2, ARG2, CHL1, PPP1R1A, TMEM37 (Fig. 2b–f),
G6PC2 and CAPN13, while four were upregulated (KCNH8,
FAM102B, FBXO32 and CD44). These 19 genes were corre-
lated with stimulated insulin secretion from OD islets (ESM
Fig. 2). Notably, nine of these genes, namely ANKRD23/39,
ASCL2, HHATL, NSG1, PCDH20, SCTR, CD44, FAM102B
and FBXO32 have not been previously reported to be dysreg-
ulated in type 2 diabetes.
Meta-analysis of a published transcriptomic dataset [20]
revealed dysregulation (FDR ≤0.05) of 114 probe sets,
corresponding to 94 unique genes. We searched this dataset
for the 19 genes dysregulated in both our islet cohorts and
found that CHL1, FFAR4 and SLC2A2 were downregulated
with an FDR of ≤0.05 and a fold change of ≥1.5, while
ANKRD23/39, ARG2, HHATL, PPP1R1A and UNC5D were
downregulated with an FDR of ≤0.1 in type 2 diabetic islets,
thus confirming the significant downregulation of CHL1,
FFAR4 and SLC2A2 in type 2 diabetic OD islets in a different
cohort.
Dysregulated genes in IGT and type 3c diabetic islets The
availability of islets from PPP with IGT or type 3c diabetes
(Table 1) allowed us to investigate the expression of the 19
genes commonly dysregulated in type 2 diabetic islets according
to the extent of hyperglycaemia (Fig. 2g). The expression of the
genes differed significantly only between type 2 diabetic and
non-diabetic PPP islets (FDR ≤0.05). Nonetheless, the fold
changes between type 3c diabetic and non-diabetic PPP
islets were in the same direction, albeit with smaller dif-
ferences than between type 2 diabetic and non-diabetic
PPP islets. The fold changes in IGT vs non-diabetic PPP
islets were low (≤1.6); only three of the 19 genes had
absolute fold changes >1.2. These diversities between is-
lets from type 2 diabetics (both OD and PPP), IGT (PPP)
and type 3c diabetics (PPP) may be due to idiosyncrasies
of these conditions and/or different duration and severity
of the hyperglycaemia.
Validation of selected genes Some (SLC2A2, CHL1,
PPP1R1A, ARG2 and TMEM37), but not all, of the 19 differen-
tially expressed genes in type 2 diabetic OD and PPP islets were
previously shown to be enriched in beta cells and altered in type
2 diabetes [15]. Among the 19 genes dysregulated in type 2
diabetic islets, ARG2 and PPP1R1A were also differentially
expressed in non-diabetic OD islets exposed ex vivo to high
glucose (22.2 mmol/l) for 48 h, while CHL1, FBX032 and
SLC2A2 showed a trend towards dysregulation (ESM Table 9).
These results, although obtained with relatively few preparations
(n = 3), suggest that the expression of several of the 19 signature
genes changes within a relatively short time span upon islet
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exposure to a ‘hyperglycaemic’milieu. Confirmation with more
samples will be required to better ascertain the precise regulation
of these genes in islets upon glucose treatment.
Consistent with recent RNA sequencing data of sorted
adult beta cells (n = 7, non-diabetic cells) [29], in situ PCR
on human pancreas sections confirmed islet expression of the
19 type 2 diabetes signature genes (ESM Fig. 3 shows images
for three representative genes). As proof of principle, we
verified protein expression and localisation of ARG2,
PPP1R1A and TMEM37 in human pancreas. ARG2 was
detected in a subset of insulin-positive and glucagon-positive
cells (Fig. 3a, ESM Fig. 4). Conversely, PPP1R1A was
co-localised with insulin-positive cells, but its expression
was weaker in glucagon-positive cells. TMEM37 was
co-localised with insulin-positive cells and some glucagon-
positive cells. Analysis of islet alpha and beta cell-enriched
fractions from five non-diabetic and four type 2 diabetic OD
by RT-qPCR showed that ARG2, PPP1R1A and TMEM37
were enriched in beta cells and downregulated in type 2 dia-
betes (Fig. 3b–d).
Silencing of either Arg2 (ESM Fig. 5a) or Ppp1r1a
(ESM Fig. 5b) in insulinoma INS-1 832/13 cells reduced
insulin secretion (Fig. 3e, f), while the opposite was ob-
served by silencing Tmem37 (Fig. 3g, ESM Fig. 5c), con-
sistent with the latter being an inhibitory subunit of
voltage-gated calcium channels [30]. Accordingly,
Tmem37 downregulation increased the proportion of cells
with elevated intracellular Ca2+ ([Ca2+]i) concentrations
(ESM Fig. 5d, e), and the peak [Ca2+] amplitudes
(Fig. 3h, ESM Fig. 5f) after exposure to high glucose.
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Overexpression of mTmem37-V5 (ESM Fig. 5g, h)
reduced insulin release (Fig. 3i) and [Ca2+]i under basal
conditions (ESM Fig. 5i) or in response to high glucose or
potassium (Fig. 3j). These data suggest that insulin secre-
tion is inhibited by downregulation of ARG2 and
PPP1R1A and enhanced by downregulation of TMEM37.
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Fig. 3 Functional validation of the dysregulated genes ARG2, PPP1R1A
and TMEM37 in insulin-producing cells. (a) Confocal microscopy of
human pancreas tissue sections co-immunostained for insulin and
ARG2, PPP1R1A or TMEM37. (b-d) RT-qPCR analysis of ARG2,
PPP1R1A and TMEM37 expression levels in human islet alpha and beta
cell-enriched fractions from ND (n = 5, black columns) and T2D (n = 4,
white columns) OD (*p < 0.05, beta vs alpha cells; †p < 0.05 T2D vs ND
beta cells, Student’s t test). (e-g) Insulin stimulation index (ISI) of INS-1
832/13 cells after silencing of Arg2 (e), Ppp1r1a (f) or Tmem37 (g)
expression with small interfering RNA (siRNA) (grey columns) vs cells
treated with a control (Ctrl siRNA, black columns) siRNA oligonucleo-
tide (*p < 0.05, **p < 0.01, Student’s t test). (h) Ca2+ concentrations in
INS-1 832/13 cells after silencing of Tmem37 (grey trace) vs cells treated
with a control (Ctrl siRNA) siRNA oligonucleotide (black trace). The
curves show the mean ± SEM Fura-2 AM ratios for 11 (n = 351
siGLO+, Ctrl siRNA-treated cells) and 12 (n = 480 siGLO+, Tmem37
siRNA-treated cells) coverslips. Changes in glucose and KCl concentra-
tions are indicated. The inset shows the mean ± SEM cumulative Ca2+
changes (AUC) in response to glucose (**p < 0.01 vs Ctrl, Mann–
Whitney U test). (i) ISI of INS-1 832/13 cells transfected with
Tmem37-V5 or the empty pcDNA3.1 vector (Ctrl) (*p < 0.05, Student’s
t test) (j) Ca2+ concentrations in eGFP+ INS-1 832/13 cells co-transfected
with Tmem37-V5 (grey trace) and eGFP+ INS-1 832/13 cells co-
transfected with the empty pcDNA3.1 vector (Ctrl) (black trace). The
curves show the mean ± SEM Fura Red ratios (R) for ten (n = 332
eGFP+, Tmem37-V5 co-transfected cells) and 12 (n = 419 eGFP+,
pcDNA3.1 co-transfected cells) coverslips. The glucose concentration
was increased from 3 to 15 mmol/l, and 20 mmol/l KCl was added at
the indicated times. The inset shows mean + SEM of the peak R ampli-
tude in response to high glucose and KCl stimulation (*p < 0.05, unpaired
two-tailed t test). ND, non-diabetic; T2D, type 2 diabetic
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Distinct sets of upstream and downstream pathways are
predicted for the OD and PPP cohorts Among the enriched
pathways related to dysregulated genes identified in type 2 dia-
betic islets (Fig. 4), several were previously found to influence
beta cell function. ‘maturity onset diabetes of young (MODY)
signalling’ and ‘neuropathic pain signalling’ were the only two
pathways in common among the top 20 identified in each cohort
separately. Differentially expressed probe sets separated for up-
regulation and downregulation were analysed for enriched gene
ontologies. Interestingly, similar biological processes were
enriched for downregulated probe sets in OD and PPP islets
(ESM Table 10) with a strong focus on hormone secretion
(ESM Table 11). Analysis of downstream functions using a
literature-based prediction method [31] revealed a decrease in
processes controlling cAMP concentrations, neurotransmitter re-
lease and synaptic transmission in OD islets, while pathways
related to numbers of beta cells, islet cells and neuroendocrine
cells were mostly affected in PPP islets (ESM Table 12).
The same method was used to identify putatively activated
or inhibited upstream regulators of the regulated genes. For
OD islets, the highest inhibition scores were found for
ADCYAP1, NEUROD1, BDNF and PAX6 (ESM Table 13),
supporting altered differentiation of beta cells during develop-
ment and/or function and viability. Significant activation
scores were found for FOXO1 and, in particular, REST, two
transcriptional regulators, which preclude the differentiation
of beta cells and/or the retention of their identity [32, 33].
HNF1Awas the only transcription factor predicted to be sig-
nificantly inhibited in PPP islets.
Analysis of potential upstream regulators revealed key
transcription factors involved in beta cell dysfunction
Gene co-expression modules were identified for non-diabetic
OD and PPP islets. Modules that significantly overlapped be-
tween OD and PPP were then correlated with clinical or func-
tional traits (see ESM Methods). This identified a set of ten
modules in which 14 out of 19 differentially expressed signa-
ture genes were enriched (hypergeometric p = 3.34 × 10−5);
only CAPN13, FFAR4, NSG1, FAM102B and KCNH8 were
absent from the selected modules. To investigate whether
genes within modules share the same transcriptional control,
we identified putative upstream transcription factors using two
complementary bioinformatics approaches (Fig. 5a). The first
used a literature-based prediction method [31], while the sec-
ond used enrichment of predicted transcription factor binding
sites in the promoter sequences of the module genes [34]. The
results were then used to generate two networks, one for each
analysis, describing predicted upstream transcription factor
interactions with their predicted target genes. The networks
were merged into a single network containing 17 up-
stream transcription factors and 29 transcription factor–
target gene interactions predicted by both approaches
(Fig. 5b, c). Several modules were correlated with insulin
and blood glucose levels (Fig. 5c and ESM Figs 6–8).
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receptor; GABA, γ-aminobutyric acid; GPCR, G protein-coupled recep-
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Of note, three of the 19 differentially expressed signature
genes (PPP1R1A, SLC2A2 and CD44) were present in this
network and were potential targets of PDX1. We therefore
hypothesised that PDX1 and other transcription factors in
the network regulate the differentially expressed genes in type
2 diabetes. The volcano plots in Figs 5d and e show the 17
transcription factors in OD and PPP islets, respectively. REST,
FOXA1 and SP1 were upregulated and HLF was downregu-
lated in OD islets. Meanwhile, PDX1, HNF1A and HLF were
downregulated in PPP islets. HNF1A tended to be downregu-
lated in OD islets. Other thanHLF, these transcription factors,
are known regulators of beta cell differentiation and function.
Validation of upstream regulators Among the transcription
factors identified above, PDX1, HNF1A and HLF were cho-
sen for further analyses. RT-qPCR assays of human islet alpha
and beta cell-enriched fractions confirmed that expression of
PDX1 and HNF1A was reduced in type 2 diabetic beta cells
(Fig. 6a, b). Although HLF was enriched in non-diabetic beta
cells, its expression was not altered in type 2 diabetes (Fig.
6c), and its role was not further investigated. Both PDX1 and
HNF1Awere detected in the nucleus of EndoC-βH1 cells [35]
(Fig. 6d). Silencing of HNF1A (Fig. 6e, ESM Fig. 9a, b) re-
duced mRNA levels of SLC2A2, PPP1R1A and TMEM37
(Fig. 6f). While SLC2A2 is a known target of HNF1A [36,
37], PPP1R1A and TMEM37 are not predicted to include a
binding site for HNF1Awithin 5 kb upstream or downstream
of their transcription start site (ESM Methods and ESM
Table 14). Silencing of PDX1 reduced SLC2A2 mRNA levels
but increased those of ANKRD23 and ARG2 (Fig. 6f). All
three genes include one or more putative binding sites for
PDX1. Chromatin immunoprecipitation assays did not pro-
vide evidence for binding of HNF1A to the promoters of
UNC5D, FAM102B and CD44, while the promoter regions
of ARG2 and SLC2A2, the latter being a well-established
PDX1 target, were recovered with PDX1 (Fig. 6g).
Discussion
Rationale and novelty of the methodological approachWe
present a novel transcriptomic signature of human type 2
diabetic islets. Our data were obtained from the rigorous
analysis of, to date, the largest collection of human islets
from non-diabetic (n = 116) and type 2 diabetic (n = 55)
individuals. We exploited two different islet sources (OD
and PPP) and islet isolation methods (enzymatic digestion
and LCM) to maximise the advantages and circumvent the
limitations of each method [38–40]. One concern is that in
PPP the underlying pancreatic disease may influence islet cell
gene expression. In our PPP cohort, the prevalence of pan-
creatitis and benign or malignant pancreatic tumours was
comparable between the non-diabetic and type 2 diabetic
PPP. None of these disorders was associated with islet tran-
scriptome changes (ESM Fig. 10), while PPP and OD islets
were equivalent in terms of the presence of ‘contaminating’
acinar and ductal cell markers. The duration of type 2 diabe-
tes in PPP (10.6 ± 8.6 years) and OD (9.9 ± 7.4 years) was
comparable and previous studies found no association be-
tween diabetes and pancreatic cancer among individuals with
long-standing type 2 diabetes [41]. PCA revealed that the
transcriptomes of islets isolated from the same organ donor
either by enzymatic digestion or by LCM did not cluster,
whereas the latter clustered with the transcriptomes of LCM
PPP islets. We further compared our results with recently
published signatures for four pancreatic cancer subtypes
[29] and found that genes differentially regulated in type 2
diabetic islets of OD and PPP showed very similar patterns of
enrichment against these signatures (ESM Table 15). These
results demonstrate that the transcriptomic differences be-
tween OD and PPP samples are not driven by patient differ-
ences, but are mainly due to the distinct islet isolation proce-
dures used in each cohort.
For transcriptomic analysis we used microarrays rather
than RNA sequencing because when we initiated the sample
processing the former offered the most robust and cost-
effective solution. In future, it will be valuable to investigate
Fig. 5 Systems biology analysis predicted the key transcription factors
(TFs) regulated in type 2 diabetes. (a)Workflow to identify upstream TFs.
(b) Schematic showing how literature and sequence-based networks were
combined to generate an intersection network. TFs are represented by
inverted triangles and genes are represented by squares. Evidence for
TF gene targets is shown by arrows (literature red, sequence-based
green). Intersection Network (orange) shows TF–target gene
interactions present in both literature and sequence-based networks.
Underneath each schematic is a hive plot showing edges between
upstream TFs, target genes and gene co-expression modules. Modules
are shown as coloured nodes on the vertical axes. TFs are represented
on the left axes and their predicted target genes on the right axes. Edges
are coloured according to the gene co-expression module of the source
node. Nodes are ordered along the axes by increasing degree from the
centre outwards. (c) Network representation of the Intersection Network
shown in (b). Gene co-expression modules are represented as large
coloured nodes in the corresponding module colour. skyblue, blue and
darkviolet modules are correlated with the insulin stimulation index (ISI)
of OD islets (solid black outlines), while lightpink4 module correlates
with glucose concentrations at 2 h after an OGTT in PPP islets (dashed
box). Yellow nodes indicate potential upstream TFs for each module.
Blue or orange nodes indicate putative target genes (TFs in orange).
Network edges were predicted by both literature and sequence motif-
based approaches. For visualisation, the network was filtered to remove
all gene nodes except for TFs with only one edge. For a more detailed
view, a PDF version of Fig. 5 is provided as ESM Fig. 11. (d, e) Volcano
plots of differentially expressed TFs in type 2 diabetic vs non-diabetic OD
(d) and PPP (e) islets. Significantly differentially regulated TFs (Limma
empirical Bayes adjusted (Benjamini Hochberg method) p ≤ 0.05, fold
change ≥1.2) are shown as red (upregulated) or blue (downregulated)
circles, while potentially differentially regulated TFs with lower fold
changes (FDR ≤0.05; no fold change cut-off) are shown as black
circles. Upregulated and downregulated TFs are also indicated on the
right of each plot. See ESM Table 13 for more details
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this large set of human islets by RNA sequencing [42], for
example, to assess alternative splice variants and the status of
non-coding RNA.
In our IGTand type 3c diabetic PPP, as in a previous cohort
of type 2 diabetic individuals undergoing surgery for
pancreatic cancer [43], glucose intolerance correlated with
altered hepatic function and insulin resistance secondary to
compression of the biliary duct by the pancreas head [7].
Indeed, equivalent types of tumours in the pancreas body
and tail were not associated with glucose intolerance, which
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Fig. 6 Validation of PDX1, HNF1A andHLF as transcription factors (TFs)
located upstream of the T2D islet signature genes. (a–c) RT-qPCR of PDX1
(a), HNF1A (b), and HLF (c) expression levels in alpha and beta cell-
enriched fractions from human ND (n = 5, black bars) and T2D (n = 4,
white bars) OD islets. *p < 0.05, Student’s t test. (d) Co-immunostaining for
insulin (green) and PDX1 or HNF1A (red) in human EndoC-βH1 cells.
Nuclei are counterstained with DAPI (blue). (e) Immunoblots for PDX1,
HNF1A or γ-tubulin in EndoC-βH1 cells treated with esiRNA for PDX1,
HNF1A or with a control esiRNA. Bar, 10 μm. (f) RT-qPCR of the 19 T2D
islet signature genes in EndoC-βH1 cells treated with esiRNA for PDX1 or
HNF1A or with a control esiRNA (*p < 0.05, †p < 0.01 and ‡p < 0.001;
ANOVA) (n = 4, except for ANKRD39, which was measured three times).
(g) Fold enrichment (y-axis) of T2D islet signature genes with predicted
binding sites for PDX1 as measured upon chromatin immunoprecipitation
with anti-PDX1 antibody vs control IgG followed by RT-qPCR with
primers flanking the predicted binding site. The values in (g) are from three
independent chromatin immunoprecipitations. esiRNA, endoribonuclease-
prepared small interfering RNA; ND, non-diabetic; T2D, type 2 diabetic
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ameliorated quickly after removing tumours in the pancreas
head [7, 44]. Hence, beta cell dysfunction and hyperglycaemia
in IGT and type 3c diabetic PPP are likely to result from the
burden that insulin resistance poses on beta cells, rather than
from a direct effect of the tumour on such cells.
Novelty and relevance of the biological findingsNone of the
19 signature genes are in any of the established type 2
diabetes-associated genetic loci [45], although G6PC2
variants affect fasting glucose [46, 47]. The activities of most
of them in beta cells are suggested by their associations with
islet functional traits and clinical variables. Some of our results
confirm previous work showing downregulation of ARG2,
CAPN13, CHL1, FFAR4, G6PC2, PPP1R1A, SLC2A2,
TMEM37 and UNC5D and upregulation of KCNH8 in type
2 diabetic islets [15, 17, 20]. The involvement of SLC2A2,
FFAR4 and G6PC2 in beta cell function is well established
[46, 48, 49], while that of CHL1 and PPP1R1Awas reported
more recently [15, 17, 50]. Using RT-qPCR and/or immuno-
staining, we showed that PPP1R1A, ARG2 and TMEM37 are
enriched in human beta cells and their modulation affects in-
sulin release. Sequence similarity suggests that TMEM37 en-
codes an evolutionarily conserved inhibitory subunit of
voltage-gated calcium channels, but its function has never
been validated. We show that its acute depletion increased
[Ca2+]i levels and insulin secretion upon glucose stimulation,
while its overexpression exerted opposite effects. Hence,
TMEM37 reduced expression in type 2 diabetic islets may
represent a compensatory effort of beta cells in response to
prolonged hyperglycaemia.
Nine genes not previously reported to be associated with
type 2 diabetes were significantly dysregulated in our organ
donor and PPP cohorts (ANKRD23/39, ASCL2, HHATL,
NSG1, PCDH20, SCTR, CD44, FAM102B and FBXO32).
Ankyrin repeat domain 23/39 (ANKRD23) is a transcriptional
regulator enriched in metabolically active tissues, such as
muscle and brown fat [51]. In muscles, it reduces serine/
threonine kinase 11 (STK11, also known as LKB1) expres-
sion, AMPK phosphorylation [52] and palmitate uptake.
Interestingly, its expression is upregulated in insulin target
tissues in rat models of type 2 diabetes [51]. Achaete-scute
complex homologue 2 (ASCL2) is a transcription factor
implicated in fate determination of neuronal precursor cells,
while hedgehog acyltransferase-like protein (HHATL) may
inhibit N-terminal protein palmitoylation. Their downregula-
tion correlated with de-differentiation of human islets in cul-
ture [53]. ASCL2, NSG1, PCDH20 and UNC5D transcripts
are enriched in neurons, which are functionally related to islet
endocrine cells. Neuron specific gene family member 1
(NSG1, also known as NEPP21) is implicated in endosomal
trafficking of neuronal cell adhesion molecule NRCAM (also
termed L1/NgCAM), of which CHL1 is a paralogue, and of
glutamate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors. A
recent study found that NMDA receptors inhibit insulin secre-
tion [54]. Unc-5 netrin receptor D (UNC5D), like neural cell
adhesion molecule L1-like protein (CHL1), may regulate neu-
ronal migration and survival [55] while protocadherin 20
(PCDH20) may inhibit the canonical WNTsignalling pathway.
Finally, secretin receptor (SCTR) is the most potent regulator of
pancreatic bicarbonate, electrolyte and volume secretion.
Although early research indicated that secretin stimulates insu-
lin release in humans [56], the role of this hormone and its
receptor in beta cell function remains unclear.
Other novel genes upregulated in type 2 diabetic islets were
CD44, FAM102B and FBXO32. CD44 is involved in cell
adhesion and migration, cell–cell interactions, islet inflamma-
tion in type 1 diabetes [57], adipose tissue inflammation, insulin
resistance and hyperglycaemia [58]. F-box protein 32
(FBXO32) belongs to the E3-ubiquitin ligase Skp1–Cullin–F-
box complex for phosphorylation-dependent ubiquitination.
Alterations of the ubiquitin–proteasome pathway are associated
with beta cell dysfunction in type 2 diabetes [14].
Our results provide new insights on islets in type 2 diabe-
tes. Upregulation of genes encoding proinflammatory mole-
cules such as IL1B, CCL26, CCL3, CCL8, CXCL1, CXCL11,
CXCL12, CXL2 and CXCR7 in type 2 diabetic OD islets, but
not in type 2 diabetic PPP islets, likely reflects a ‘wound’
response secondary to enzymatic isolation [53]. The top genes
relevant to beta cell function and downregulated in type 2
diabetic OD islets were GLP1R, IAPP, PTPRN, ERO1LB,
ALDOC and the genes encoding several glutamate AMPA
and NMDA receptor subunits, namely GRIA2, GRIA4 and
GRIN2A. The top upregulated genes in type 2 diabetic PPP
islets were the aldolase isoform ALDOB and FAIM2, while
TMEM27 and GRIN2D were downregulated.
Using a novel network-based strategy, we inferred altered
activities of PDX1, HNF1A and HLF in type 2 diabetic islets.
Both PDX1 and HNF1Awere downregulated in enriched beta
cell fractions from type 2 diabetic OD, with PDX1 targeting
ARG2. Downregulation of HNF1A, which lies upstream of
PDX1, and upregulation of REST, point to de-differentiation
of beta cells in type 2 diabetes. However, this suggestion is
tempered by the lack of evidence for upregulation of the so-
called ‘disallowed’ beta cell genes [59], as expected in the
context of clear de-differentiation. More sensitive approaches,
such as RNA sequencing, may be required to detect changes
in these weakly expressed genes.
The present results likely represent only the tip of the ice-
berg in terms of potential targets and biological hypotheses for
beta cell alterations in type 2 diabetes. Several other groups
have published findings derived from OD islets [11–20].
Since all these studies, including our own, are each likely to
capture only part of the ‘truth’, a more complete picture will
conceivably emerge from the integration of all available hu-
man islet transcriptomic datasets.
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An intriguing finding is that none of the 19 signature genes
showed significant expression changes in type 3c diabetes or IGT
PPP islets. While these findings must be validated in larger co-
horts, one implication is that the diverse transcriptomic changes
in type 2 diabetic, IGT and type 3c diabetic islets may reflect
pathophysiological idiosyncrasies of these conditions and/or the
duration and severity of hyperglycaemia. Another possibility is
that these transcriptomic changes correlate with beta cell failure
but may not precede it. Therefore, islet transcriptomic changes
preceding beta cell failure remain elusive.
In conclusion, the present study provides a stringent defi-
nition of the transcriptomic signature of a large series of hu-
man type 2 diabetic islets, regardless of islet source and isola-
tion procedure. The identification of dysregulated genes, some
of them not reported previously, the description of down-
stream and upstream regulators and the identification of key
transcription factors involved in beta cell dysfunction, as re-
ported in this study, contribute to the understanding of the
complex molecular scenario of type 2 diabetic islet cells.
Acknowledgements Open access funding provided by Max Planck
Society. We dedicate this work to A. Ktorza (Servier, Paris, France), an
excellent scientist and friend who left us. We thank W. Kramer
(Coordinator IMIDIA, Frankfurt, Germany), P. Hecht (Alliance and
Operations Manager IMIDIA, Graz, Austria), V. Koivisto (Eli Lilly,
Bad Homburg, Germany), and all the members of the IMIDIA consor-
tium for their support and advice. We thank E. Schöniger and N. Radish
(PLID, Dresden, Germany) and M. Marcelo (Eli Lilly, Indianapolis, IN,
USA) for excellent technical assistance, H. Hartmann (TU Dresden,
Dresden, Germany) and B. Schroth-Diez (MPI-CBG, Dresden,
Germany) for their advice. We thank F. Möller (PLID, Dresden,
Germany) and N. Smith (AMICULUM, Auckland, New Zealand) for
his editorial support. Some of the data were presented as an abstract at
the 52nd EASD Annual Meeting in 2016.
Data availability Raw microarray data have been deposited in a
MIAME-compliant database (GEO, accession number: GSE76896).
Funding The work was supported by the Innovative Medicines
Initiative Joint Undertaking (grant no. 155005) for IMIDIA, which re-
ceived financial contributions from the European Union’s Seventh
Framework Program (FP7/2007–2013); companies belonging to the
European Federation of Pharmaceutical Industries and Associations; the
German Center for Diabetes Research (DZD e.V.), which is supported by
the German Ministry for Education and Research (to MSo); the Italian
Ministry of Education and Research (Prin 2010–2011) (to PMa); the
Wellcome Trust (Advanced Investigator Award WT098424AIA); the
Medical Research Council (Program MR/J0003042/1); and the Royal
Society (Wolfson Research Merit Award) (to GAR).
Duality of interest AMS, BM-P, DM and MvB are employees of
Sanofi-Aventis; KB was an employee of Eli Lilly; EN is an employee
of F. Hoffmann-La Roche. The remaining authors declare that there is no
duality of interest associated with this manuscript.
Contribution statement FE, DR, MK, MD, RG, KP, JM, GB, DS, H-
DS and JWacquired and interpreted clinical data fromPPP.DR,DS andMK
isolated islets by laser capture microscopy. PMa, LM, MB, MSu, FS, UB,
FF, CBWand KB acquired and interpreted data on OD. LM,MB,MSu, FS,
and CBW isolated islets and single cells by enzymatic isolation and cell
sorting, respectively. AMS, BM-P, DM and MvB performed transcriptomic
and bioinformatic analyses of islet samples together with MI, IX, FB, RL,
EP, ASi, MF, AM-M, LW,ML and AD. LM, HM, K-PK, JP, MB, AJ, CW,
ASö, AF, CBW, RS, BM-P, SL and GAR validated genes of interest and
contributed to the interpretation of the corresponding data. EB acquired and
interpreted data on antibodies for type 1 diabetes autoantigens. MSo, AMS,
PMa, PF and MI designed the study with contributions from PMe, SL, EN,
and BT. MSo, AMS, MI and PMa coordinated the project and wrote the
manuscript with contributions from MvB, LM, DR, HM, K-PK, KP, GAR
and PF. All authors contributed either to the drafting of the work and/or its
critical revision and approved the final version of the manuscript. MSo,
AMS, MI and PMa are the guarantors of this work.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Fuchsberger C, Flannick J, Teslovich TM et al (2016) The genetic
architecture of type 2 diabetes. Nature 536:41–47
2. Halban PA, Polonsky KS, Bowden DWet al (2014)β-cell failure in
type 2 diabetes: postulated mechanisms and prospects for preven-
tion and treatment. Diabetes Care 37:1751–1758
3. Kahn SE (2003) The relative contributions of insulin resistance and
beta-cell dysfunction to the pathophysiology of type 2 diabetes.
Diabetologia 46:3–19
4. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008)
Pancreatic beta-cell mass in European subjects with type 2 diabetes.
Diabetes Obes Metab 10(Suppl 4):32–42
5. Marselli L, SuleimanM,MasiniM et al (2014)Arewe overestimating
the loss of beta cells in type 2 diabetes? Diabetologia 57:362–365
6. Mingrone G, Panunzi S, De Gaetano A et al (2012) Bariatric sur-
gery versus conventional medical therapy for type 2 diabetes. N
Engl J Med 366:1577–1585
7. Ehehalt F, SturmD, RoslerM et al (2015) Blood glucose homeostasis
in the course of partial pancreatectomy—evidence for surgically re-
versible diabetes induced by cholestasis. PLoS One 10:e0134140
8. Steven S, Hollingsworth KG, Al-Mrabeh A et al (2016) Very low-
calorie diet and 6 months of weight stability in type 2 diabetes:
pathophysiological changes in responders and nonresponders.
Diabetes Care 39:808–815
9. Cinti F, Bouchi R, Kim-Muller JY et al (2016) Evidence of β-cell
dedifferentiation in human type 2 diabetes. J Clin EndocrinolMetab
101:1044–1054
10. Dor Y, Glaser B (2013) β-cell dedifferentiation and type 2 diabetes.
N Engl J Med 368:572–573
11. Gunton JE, Kulkarni RN, Yim S et al (2005) Loss of ARNT/HIF1β
mediates altered gene expression and pancreatic-islet dysfunction in
human type 2 diabetes. Cell 122:337–349
12. MacDonaldMJ, LongacreMJ, Langberg EC et al (2009) Decreased
levels of metabolic enzymes in pancreatic islets of patients with
type 2 diabetes. Diabetologia 52:1087–1091
13. Ostenson CG, Gaisano H, Sheu L, Tibell A, Bartfai T (2006)
Impaired gene and protein expression of exocytotic soluble N-
ethylmaleimide attachment protein receptor complex proteins in
pancreatic islets of type 2 diabetic patients. Diabetes 55:435–440
14. Bugliani M, Liechti R, Cheon H et al (2013) Microarray analysis of
isolated human islet transcriptome in type 2 diabetes and the role of
the ubiquitin-proteasome system in pancreatic beta cell dysfunc-
tion. Mol Cell Endocrinol 367:1–10
15. Taneera J, Lang S, Sharma A et al (2012) A systems genetics ap-
proach identifies genes and pathways for type 2 diabetes in human
islets. Cell Metab 16:122–134
656 Diabetologia (2018) 61:641–657
16. Fadista J, Vikman P, Laakso EO et al (2014) Global genomic and
transcriptomic analysis of human pancreatic islets reveals novel
genes influencing glucose metabolism. Proc Natl Acad Sci U S A
111:13924–13929
17. Taneera J, Fadista J, Ahlqvist E (2015) Identification of novel genes for
glucose metabolism based upon expression pattern in human islets and
effect on insulin secretion andglycemia.HumMolGenet 24:1945–1955
18. Andersson SA, Olsson AH, Esguerra JL et al (2012) Reduced in-
sulin secretion correlates with decreased expression of exocytotic
genes in pancreatic islets from patients with type 2 diabetes. Mol
Cell Endocrinol 364:36–45
19. Taneera J, Fadista J, Ahlqvist E et al (2013) Expression profiling of
cell cycle genes in human pancreatic islets with and without type 2
diabetes. Mol Cell Endocrinol 375:35–42
20. Mahdi T, Hanzelmann S, Salehi A et al (2012) Secreted frizzled-
related protein 4 reduces insulin secretion and is overexpressed in
type 2 diabetes. Cell Metab 16:625–633
21. Xin Y, Kim J, Okamoto H et al (2016) RNA sequencing of single
human islet cells reveals type 2 diabetes genes. CellMetab 24:608–615
22. Segerstolpe A, Palasantza A, Eliasson P et al (2016) Single-cell
transcriptome profiling of human pancreatic islets in health and type
2 diabetes. Cell Metab 24:593–607
23. Marselli L, Thorne J, Dahiya S et al (2010) Gene expression pro-
files of beta-cell enriched tissue obtained by laser capture microdis-
section from subjects with type 2 diabetes. PLoS One 5:e11499
24. Del Guerra S, Lupi R, Marselli L et al (2005) Functional and mo-
lecular defects of pancreatic islets in human type 2 diabetes.
Diabetes 54:727–735
25. Sturm D, Marselli L, Ehehalt F et al (2013) Improved protocol
for laser microdissection of human pancreatic islets from sur-
gical specimens. J Vis Exp 71:50231
26. Kirkpatrick CL, Marchetti P, Purrello F et al (2010) Type 2 diabetes
susceptibility gene expression in normal or diabetic sorted human
alpha and beta cells: correlations with age or BMI of islet donors.
PLoS One 5:e11053
27. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD
(2012) Prevalence of diabetes mellitus secondary to pancreatic diseases
(type 3c). Diabetes Metab Res Rev 28:338–342
28. Bailey P, Chang DK, Nones K et al (2016) Genomic analyses iden-
tify molecular subtypes of pancreatic cancer. Nature 531:47–52
29. Blodgett DM, Nowosielska A, Afik S et al (2015) Novel observa-
tions from next-generation RNA sequencing of highly purified hu-
man adult and fetal islet cell subsets. Diabetes 64:3172–3181
30. Chu PJ, Robertson HM, Best PM (2001) Calcium channel gamma
subunits provide insights into the evolution of this gene family.
Gene 280:37–48
31. Kramer A, Green J, Pollard J Jr, Tugendreich S (2014) Causal analysis
approaches in ingenuity pathway analysis. Bioinformatics 30:523–530
32. Atouf F, Czernichow P, Scharfmann R (1997) Expression of neu-
ronal traits in pancreatic beta cells. Implication of neuron-restrictive
silencing factor/repressor element silencing transcription factor, a
neuron-restrictive silencer. J Biol Chem 272:1929–1934
33. Talchai C, Xuan S, Lin HV, Sussel L, Accili D (2012) Pancreatic beta
cell dedifferentiation as a mechanism of diabetic beta cell failure.
Cell 150:1223–1234
34. Kwon AT, Arenillas DJ, Worsley Hunt R, Wasserman WW (2012)
oPOSSUM-3: advanced analysis of regulatory motif over-
representation across genes or ChIP-Seq datasets. G3 (Bethesda)
2:987–1002
35. Ravassard P, Hazhouz Y, Pechberty S et al (2011) A genetically
engineered human pancreatic beta cell line exhibiting glucose-
inducible insulin secretion. J Clin Invest 121:3589–3597
36. PárrizasM,MaestroMA, Boj SF et al (2001) Hepatic nuclear factor
1-alpha directs nucleosomal hyperacetylation to its tissue-specific
transcriptional targets. Mol Cell Biol 21:3234–3243
37. Holmkvist J, Cervin C, Lyssenko V et al (2006) Common var-
iants in HNF-1 alpha and risk of type 2 diabetes. Diabetologia
49:2882–2891
38. In’t Veld P, De Munck N, Van Belle K et al (2010) Beta-cell repli-
cation is increased in donor organs from young patients after
prolonged life support. Diabetes 59:1702–1708
39. Toyama H, Takada M, Suzuki Y, Kuroda Y (2003) Activation of
macrophage-associated molecules after brain death in islets. Cell
Transplant 12:27–32
40. Ebrahimi A, JungMH, Dreyfuss JM et al (2017) Evidence of stress
in β cells obtained with laser capture microdissection from
pancreases of brain dead donors. Islets 9:19–29
41. Gullo L, Pezzilli R, Morselli-Labate AM (1994) Diabetes and the
risk of pancreatic cancer. N Engl J Med 331:81–84
42. SonesonC,MatthesKL,NowickaM,LawCW,RobinsonMD (2016)
Isoform prefiltering improves performance of count-based methods
for analysis of differential transcript usage. Genome Biol 17:12
43. Permert J, Larsson J, Westermark GTet al (1994) Islet amyloid poly-
peptide in patients with pancreatic cancer and diabetes. N Engl JMed
330:313–318
44. Kang MJ, Jung HS, Jang JY et al (2016) Metabolic effect of
pancreatoduodenectomy: resolution of diabetes mellitus after sur-
gery. Pancreatology 16:272–277
45. Franks PW, Pearson E, Florez JC (2013) Gene-environment and
gene-treatment interactions in type 2 diabetes: progress, pitfalls,
and prospects. Diabetes Care 36:1413–1421
46. O’Brien RM (2013) Moving on from GWAS: functional studies on
the G6PC2 gene implicated in the regulation of fasting blood glu-
cose. Curr Diab Rep 13:768–777
47. Wessel J, Chu AY, Willems SM et al (2015) Low-frequency and
rare exome chip variants associate with fasting glucose and type 2
diabetes susceptibility. Nat Commun 6:5897
48. Hutton JC, O’Brien RM (2009) Glucose-6-phosphatase catalytic
subunit gene family. J Biol Chem 284:29241–29245
49. Thorens B (2015) GLUT2, glucose sensing and glucose homeosta-
sis. Diabetologia 58:221–232
50. Jiang L, Brackeva B, Ling Z et al (2013) Potential of protein phos-
phatase inhibitor 1 as biomarker of pancreatic beta-cell injury
in vitro and in vivo. Diabetes 62:2683–2688
51. Ikeda K, Emoto N, Matsuo M, Yokoyama M (2003) Molecular identi-
fication and characterization of a novel nuclear proteinwhose expression
is up-regulated in insulin-resistant animals. J Biol Chem278:3514–3520
52. Shimoda Y, Matsuo K, Kitamura Yet al (2015) Diabetes-related anky-
rin repeat protein (DARP/Ankrd23) modifies glucose homeostasis by
modulatingAMPKactivity in skeletal muscle. PLoSOne 10:e0138624
53. Negi S, Jetha A, Aikin R, Hasilo C, Sladek R, Paraskevas S (2012)
Analysis of beta-cell gene expression reveals inflammatory signaling
and evidence of dedifferentiation following human islet isolation and
culture. PLoS One 7:e30415
54. Marquard J, Otter S, Welters A et al (2015) Characterization of
pancreatic NMDA receptors as possible drug targets for diabetes
treatment. Nat Med 21:363–372
55. Takemoto M, Hattori Y, Zhao H et al (2011) Laminar and areal
expression of unc5d and its role in cortical cell survival. Cereb
Cortex 21:1925–1934
56. Lerner RL, Porte D Jr (1970) Uniphasic insulin responses to secre-
tin stimulation in man. J Clin Invest 49:2276–2280
57. Savinov AY, Strongin AY (2007) Defining the roles of T cell mem-
brane proteinase and CD44 in type 1 diabetes. IUBMB Life 59:6–13
58. Kodama K, Toda K, Morinaga S, Yamada S, Butte AJ (2015) Anti-
CD44 antibody treatment lowers hyperglycemia and improves in-
sulin resistance, adipose inflammation, and hepatic steatosis in diet-
induced obese mice. Diabetes 64:867–875
59. Pullen TJ, Khan AM, Barton G, Butcher SA, Sun G, Rutter GA
(2010) Identification of genes selectively disallowed in the pancreatic
islet. Islets 2:89–95
Diabetologia (2018) 61:641–657 657
